Commensal Microbiota and Cancer Immunotherapy: Harnessing Commensal Bacteria for Cancer Therapy

키워드

참고문헌 (89)

1. Sung H, "Global cancer statistics 2020 : Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 71, pp.209~249 (2021)
2. DeVita VT Jr, "Two hundred years of cancer research", N Engl J Med, 366, pp.2207~2214 (2012)
3. Zitvogel L, "Immunological aspects of cancer chemotherapy", Nat Rev Immunol, 8, pp.59~73 (2008)
4. Torti D, "Oncogene addiction as a foundational rationale for targeted anti-cancer therapy : promises and perils", EMBO Mol Med, 3, pp.623~636 (2011)
5. Waldman AD, "A guide to cancer immunotherapy : from T cell basic science to clinical practice", Nat Rev Immunol, 20, pp.651~668 (2020)
6. Pardoll DM, "The blockade of immune checkpoints in cancer immunotherapy", Nat Rev Cancer, 12, pp.252~264 (2012)
7. Seongju Jeong, "Co-Stimulatory Receptors in Cancers and Their Implications for Cancer Immunotherapy", Immune Network, 20(1), pp.1~20 (2020), 대한면역학회[DOI]
8. Twomey JD, "Cancer immunotherapy update : FDA-approved checkpoint inhibitors and companion diagnostics", AAPS J, 23, pp.39~ (2021)
9. Bagchi S, "Immune checkpoint inhibitors for the treatment of cancer : clinical impact and mechanisms of response and resistance", Annu Rev Pathol, 16, pp.223~249 (2021)
10. Borghaei H, "Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer", N Engl J Med, 373, pp.1627~1639 (2015)
11. Motzer RJ, "Nivolumab versus everolimus in advanced renal-cell carcinoma", N Engl J Med, 373, pp.1803~1813 (2015)
12. Robert C, "Pembrolizumab versus ipilimumab in advanced melanoma(KEYNOTE-006) : post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study", Lancet Oncol, 20, pp.1239~1251 (2019)
13. Topalian SL, "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer", N Engl J Med, 366, pp.2443~2454 (2012)
14. Havel JJ, "The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy", Nat Rev Cancer, 19, pp.133~150 (2019)
15. Rousseau B, "The spectrum of benefit from checkpoint blockade in hypermutated tumors", N Engl J Med, 384, pp.1168~1170 (2021)
16. Gopalakrishnan V, "The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy", Cancer Cell, 33, pp.570~580 (2018)
17. Kramer MG, "Bacterial therapy of cancer : Promises, limitations, and insights for future directions", Front Microbiol, 9, pp.16~ (2018)
18. Sedighi M, "Therapeutic bacteria to combat cancer; current advances, challenges, and opportunities", Cancer Med, 8, pp.3167~3181 (2019)
19. Gilbert JA, "Current understanding of the human microbiome", Nat Med, 24, pp.392~400 (2018)
20. International Human Genome Sequencing Consortium, "Finishing the euchromatic sequence of the human genome", Nature, 431, pp.931~945 (2004)
21. Turnbaugh PJ, "The human microbiome project", Nature, 449, pp.804~810 (2007)
22. Ursell LK, "Defining the human microbiome", Nutr Rev, 70(Suppl 1), pp.S38~S44 (2012)
23. Underhill DM, "Élie Metchnikoff(1845-1916) : celebrating 100years of cellular immunology and beyond", Nat Rev Immunol, 16, pp.651~656 (2016)
24. Hooper LV, "Immune adaptations that maintain homeostasis with the intestinal microbiota", Nat Rev Immunol, 10, pp.159~169 (2010)
25. Lo BC, "Gut microbiota and systemic immunity in health and disease", Int Immunol, 33, pp.197~209 (2021)
26. Mazmanian SK, "An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system", Cell, 122, pp.107~118 (2005)
27. Belkaid Y, "Role of the microbiota in immunity and inflammation", Cell, 157, pp.121~141 (2014)
28. Price AE, "A map of toll-like receptor expression in the intestinal epithelium reveals distinct spatial, cell type-specific, and temporal patterns", Immunity, 49, pp.560~575 (2018)
29. BrestoffJR, "Commensal bacteria at the interface of host metabolism and the immune system", Nat Immunol, 14, pp.676~684 (2013)
30. Jacobson A, "The intestinal neuro-immune axis : crosstalk between neurons, immune cells, and microbes", Mucosal Immunol, 14, pp.555~565 (2021)
31. Morton AM, "Endoscopic photoconversion reveals unexpectedly broad leukocyte trafficking to and from the gut", Proc Natl Acad Sci U S A, 111, pp.6696~6701 (2014)
32. Khosravi A, "Gut microbiota promote hematopoiesis to control bacterial infection", Cell Host Microbe, 15, pp.374~381 (2014)
33. Lee S, "Bone marrow CX3CR1+ mononuclear cells relay a systemic microbiota signal to control hematopoietic progenitors in mice", Blood, 134, pp.1312~1322 (2019)
34. Round JL, "Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota", Proc Natl Acad Sci U S A, 107, pp.12204~12209 (2010)
35. Round JL, "The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota", Science, 332, pp.974~977 (2011)
36. Telesford KM, "A commensal symbiotic factor derived from Bacteroides fragilis promotes human CD39+Foxp3+ T cells and Treg function", Gut Microbes, 6, pp.234~242 (2015)
37. Atarashi K, "Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota", Nature, 500, pp.232~236 (2013)
38. Atarashi K, "Induction of colonic regulatory T cells by indigenous Clostridium species", Science, 331, pp.337~341 (2011)
39. Atarashi K, "Th17 cell induction by adhesion of microbes to intestinal epithelial cells", Cell, 163, pp.367~380 (2015)
40. Goto Y, "Segmented filamentous bacteria antigens presented by intestinal dendritic cells drive mucosal Th17 cell differentiation", Immunity, 40, pp.594~607 (2014)
41. Sano T, "An IL-23R", IL-22 circuit regulates epithelial serum amyloid a to promote local effector Th17 responses, 2015, pp.163, 381~393
42. Ladinsky MS, "Endocytosis of commensal antigens by intestinal epithelial cells regulates mucosal T cell homeostasis", Science, 363, pp.eaat4042~ (2019)
43. Ivanov II, "Induction of intestinal Th17 cells by segmented filamentous bacteria", Cell, 139, pp.485~498 (2009)
44. Ansaldo E, "Akkermansia muciniphila induces intestinal adaptive immune responses during homeostasis", Science, 364, pp.1179~1184 (2019)
45. Chai JN, "Helicobacter species are potent drivers of colonic T cell responses in homeostasis and inflammation", Sci Immunol, 2, pp.eaal5068~ (2017)
46. Xu M, "c-MAFdependent regulatory T cells mediate immunological tolerance to a gut pathobiont", Nature, 554, pp.373~377 (2018)
47. Atarashi K, "Ectopic colonization of oral bacteria in the intestine drives Th1 cell induction and inflammation", Science, 358, pp.359~365 (2017)
48. Smith PM, "The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis", Science, 341, pp.569~573 (2013)
49. Haghikia A, "Dietary fatty acids directly impact central nervous system autoimmunity via the small intestine", Immunity, 43, pp.817~829 (2015)
50. Hang S, "Bile acid metabolites control Th17 and Treg cell differentiation", Nature, 576, pp.143~148 (2019)
51. Atarashi K, "ATP drives lamina propria Th17 cell differentiation", Nature, 455, pp.808~812 (2008)
52. Tanoue T, "A defined commensal consortium elicits CD8 T cells and anti-cancer immunity", Nature, 565, pp.600~605 (2019)
53. Luu M, "Regulation of the effector function of CD8+ T cells by gut microbiota-derived metabolite butyrate", Sci Rep, 8, pp.14430~ (2018)
54. Bachem A, "Microbiota-derived short-chain fatty acids promote the memory potential of antigen-activated CD8+ T cells", Immunity, 51, pp.285~297 (2019)
55. Luu M, "Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer", Nat Commun, 12, pp.4077~ (2021)
56. Dobosz P, "The intriguing history of cancer immunotherapy", Front Immunol, 10, pp.2965~ (2019)
57. Oiseth SJ, "Cancer immunotherapy : a brief review of the history, possibilities, and challenges ahead", J Cancer Metastasis Treat, 3, pp.250~261 (2017)
58. AlexandroffAB, "BCG immunotherapy of bladder cancer : 20 years on", Lancet, 353, pp.1689~1694 (1999)
59. Paavonen J, "Efficacy of human papillomavirus(HPV)-16", 18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types(PATRICIA) : final analysis of a double-blind, randomised study in young women, 2009, pp.374, 301~314
60. Viaud S, "The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide", Science, 342, pp.971~976 (2013)
61. Iida N, "Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment", Science, 342, pp.967~970 (2013)
62. Vétizou M, "Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota", Science, 350, pp.1079~1084 (2015)
63. Sivan A, "Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1efficacy", Science, 350, pp.1084~1089 (2015)
64. Routy B, "Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors", Science, 359, pp.91~97 (2018)
65. Gopalakrishnan V, "Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients", Science, 359, pp.97~103 (2018)
66. Matson V, "The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients", Science, 359, pp.104~108 (2018)
67. Picard C, "Review article : bifidobacteria as probiotic agents--physiological effects and clinical benefits", Aliment Pharmacol Ther, 22, pp.495~512 (2005)
68. Freitas AC, "Bifidobacteria isolated from vaginal and gut microbiomes are indistinguishable by comparative genomics", PLoS One, 13, pp.e0196290~ (2018)
69. O’Callaghan A, "Bifidobacteria and their role as members of the human gut microbiota", Front Microbiol, 7, pp.925~ (2016)
70. Lee SH, "Bifidobacterium bifidum strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice", Nat Microbiol, 6, pp.277~288 (2021)
71. Shi Y, "Intratumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING signaling", J Exp Med, 217, pp.e20192282~ (2020)
72. Mager LF, "Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy", Science, 369, pp.1481~1489 (2020)
73. Derrien M, "Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium", Int J Syst Evol Microbiol, 54, pp.1469~1476 (2004)
74. Everard A, "Cross-talk between Akkermansia muciniphila and intestinal epithelium controls dietinduced obesity", Proc Natl Acad Sci U S A, 110, pp.9066~9071 (2013)
75. Derrien M, "Akkermansia muciniphila and its role in regulating host functions", Microb Pathog, 106, pp.171~181 (2017)
76. Collado MC, "Intestinal integrity and Akkermansia muciniphila, a mucin-degrading member of the intestinal microbiota present in infants, adults, and the elderly", Appl Environ Microbiol, 73, pp.7767~7770 (2007)
77. Zheng Y, "Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma", J Immunother Cancer, 7, pp.193~ (2019)
78. Fisher K, "The ecology, epidemiology and virulence of Enterococcus", Microbiology(Reading), 155, pp.1749~1757 (2009)
79. Hanchi H, "The genus enterococcus : between probiotic potential and safety concerns-an update", Front Microbiol, 9, pp.1791~ (2018)
80. Daillère R, "Enterococcus hirae and Barnesiella intestinihominis facilitate cyclophosphamideinduced therapeutic immunomodulatory effects", Immunity, 45, pp.931~943 (2016)
81. Griffin ME, "Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor cancer immunotherapy", Science, 373, pp.1040~1046 (2021)
82. Wexler HM, "Bacteroides : the good, the bad, and the nitty-gritty", Clin Microbiol Rev, 20, pp.593~621 (2007)
83. Frankel AE, "Metagenomic shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma patients", Neoplasia, 19, pp.848~855 (2017)
84. Martín R, "Functional characterization of novel Faecalibacterium prausnitzii strains isolated from healthy volunteers : a step forward in the use of F. prausnitzii as a next-generation probiotic", Front Microbiol, 8, pp.1226~ (2017)
85. Coutzac C, "Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer", Nat Commun, 11, pp.2168~ (2020)
86. Chaput N, "Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab", Ann Oncol, 28, pp.1368~1379 (2017)
87. Davar D, "Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients", Science, 371, pp.595~602 (2021)
88. Baruch EN, "Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients", Science, 371, pp.602~609 (2021)
89. DeFilipp Z, "Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant", N Engl J Med, 381, pp.2043~2050 (2019)

관련 논문AI추천